These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 30638432)
21. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT). Aldalaan AM; Saleemi SA; Weheba I; Abdelsayed A; Aleid MM; Alzubi F; Zaytoun H; Alharbi N Pulm Circ; 2022 Apr; 12(2):e12083. PubMed ID: 35514768 [TBL] [Abstract][Full Text] [Related]
22. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153 [TBL] [Abstract][Full Text] [Related]
23. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Sulica R; Fenton R; Cefali F Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969 [TBL] [Abstract][Full Text] [Related]
24. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease]. Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483 [No Abstract] [Full Text] [Related]
25. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669 [TBL] [Abstract][Full Text] [Related]
26. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C; N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377 [TBL] [Abstract][Full Text] [Related]
27. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension]. Moiseeva OM; Rudakova AV Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734 [TBL] [Abstract][Full Text] [Related]
28. [Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study]. Zhang C; Huang Y; Huang T; Xia C; Huang X; Zhang G; Yao H; Chen J; Chen J; Wu S; Zhuang J Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):474-80. PubMed ID: 25164220 [TBL] [Abstract][Full Text] [Related]
29. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379 [TBL] [Abstract][Full Text] [Related]
30. Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. Haarman MG; Lévy M; Roofthooft MTR; Douwes JM; Vissia-Kazemier TR; Szezepanski I; Berger RMF; Bonnet D Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32855224 [TBL] [Abstract][Full Text] [Related]
32. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947 [TBL] [Abstract][Full Text] [Related]
33. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension? van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452 [TBL] [Abstract][Full Text] [Related]
35. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961 [TBL] [Abstract][Full Text] [Related]
36. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034 [TBL] [Abstract][Full Text] [Related]
37. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642 [TBL] [Abstract][Full Text] [Related]
38. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study. Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771 [TBL] [Abstract][Full Text] [Related]